JP2018510219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510219A5 JP2018510219A5 JP2018500271A JP2018500271A JP2018510219A5 JP 2018510219 A5 JP2018510219 A5 JP 2018510219A5 JP 2018500271 A JP2018500271 A JP 2018500271A JP 2018500271 A JP2018500271 A JP 2018500271A JP 2018510219 A5 JP2018510219 A5 JP 2018510219A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- sequence
- nucleic acid
- acid sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725303 Human immunodeficiency virus Species 0.000 claims 45
- 150000007523 nucleic acids Chemical group 0.000 claims 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 108091033409 CRISPR Proteins 0.000 claims 20
- 238000010354 CRISPR gene editing Methods 0.000 claims 13
- 108010042407 Endonucleases Proteins 0.000 claims 12
- 102000004533 Endonucleases Human genes 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 108020005004 Guide RNA Proteins 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 8
- 108091027981 Response element Proteins 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 108091092724 Noncoding DNA Proteins 0.000 claims 5
- 108091081548 Palindromic sequence Proteins 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 108091032955 Bacterial small RNA Proteins 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- 210000005260 human cell Anatomy 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 239000000084 colloidal system Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000032420 Latent Infection Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136080P | 2015-03-20 | 2015-03-20 | |
| US62/136,080 | 2015-03-20 | ||
| PCT/US2016/023170 WO2016154016A2 (en) | 2015-03-20 | 2016-03-18 | Tat-induced crispr/endonuclease-based gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018510219A JP2018510219A (ja) | 2018-04-12 |
| JP2018510219A5 true JP2018510219A5 (enExample) | 2019-04-25 |
Family
ID=56979180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500271A Pending JP2018510219A (ja) | 2015-03-20 | 2016-03-18 | Ｔａｔ誘導性ｃｒｉｓｐｒ／エンドヌクレアーゼに基づく遺伝子編集 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20180073019A1 (enExample) |
| EP (1) | EP3271021A4 (enExample) |
| JP (1) | JP2018510219A (enExample) |
| KR (1) | KR20170137114A (enExample) |
| CN (1) | CN107949424B (enExample) |
| AU (1) | AU2016235472A1 (enExample) |
| BR (1) | BR112017019966A2 (enExample) |
| CA (1) | CA2980317A1 (enExample) |
| EA (1) | EA201792092A1 (enExample) |
| HK (1) | HK1254230A1 (enExample) |
| IL (1) | IL254480A0 (enExample) |
| MA (1) | MA41382A (enExample) |
| MX (1) | MX2017011829A (enExample) |
| SG (2) | SG10201908773UA (enExample) |
| WO (1) | WO2016154016A2 (enExample) |
| ZA (1) | ZA201706236B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| IL297017A (en) | 2015-10-08 | 2022-12-01 | Harvard College | Multiplexed genome editing |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| EP3463290A4 (en) * | 2016-06-03 | 2019-10-30 | Temple University - Of The Commonwealth System of Higher Education | REGULATION OF THE NEGATIVE RECONSTITUTION OF HIV-1 BY GENETIZATION STRATEGY |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018194876A1 (en) * | 2017-04-17 | 2018-10-25 | Temple University- Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
| US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| CN108559730B (zh) * | 2018-01-12 | 2021-09-24 | 中国人民解放军第四军医大学 | 利用CRISPR/Cas9技术构建Hutat2:Fc基因敲入单核细胞的实验方法 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020081922A1 (en) * | 2018-10-18 | 2020-04-23 | University Of Utah Research Foundation | Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| EP3890473A4 (en) * | 2018-12-04 | 2022-09-07 | Syngenta Crop Protection AG | GEN TURN OFF VIA GENO EDITING |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020160412A1 (en) * | 2019-02-01 | 2020-08-06 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions targeting virus genomes |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| US11643672B2 (en) * | 2021-10-01 | 2023-05-09 | The Florida International University Board Of Trusters | Inducible CRISPR system expression and applications thereof |
| CN119372255A (zh) * | 2023-07-27 | 2025-01-28 | 中国科学院武汉病毒研究所 | 一种重组病毒载体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5306631A (en) * | 1987-08-21 | 1994-04-26 | University Of Colorado Foundation, Inc. | Compositions and method for inhibition of HIV production |
| US5693508A (en) * | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| US5853716A (en) * | 1995-07-28 | 1998-12-29 | Yale University | Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators |
| EP1003894A2 (en) * | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| FR2893631A1 (fr) * | 2005-11-21 | 2007-05-25 | Chu Nice | Promoteurs inductibles |
| EP2491785A1 (en) * | 2006-11-21 | 2012-08-29 | Purdue Research Foundation | Method and compositions for treating HIV infections |
| EP2405945A4 (en) * | 2009-03-13 | 2012-09-12 | Lentigen Corp | NON-INTEGRAL RETROVIRAL VECTOR VACCINES |
| US11274305B2 (en) * | 2013-04-04 | 2022-03-15 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of HIV-1 proviral DNA |
| AU2014312123A1 (en) * | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| CN104263745B (zh) * | 2014-09-16 | 2017-06-09 | 中国医学科学院医学实验动物研究所 | 一种重组免疫缺陷质粒和病毒以及应用 |
-
2016
- 2016-03-17 MA MA041382A patent/MA41382A/fr unknown
- 2016-03-18 CN CN201680029128.8A patent/CN107949424B/zh active Active
- 2016-03-18 KR KR1020177030267A patent/KR20170137114A/ko not_active Withdrawn
- 2016-03-18 EA EA201792092A patent/EA201792092A1/ru unknown
- 2016-03-18 WO PCT/US2016/023170 patent/WO2016154016A2/en not_active Ceased
- 2016-03-18 CA CA2980317A patent/CA2980317A1/en not_active Abandoned
- 2016-03-18 SG SG10201908773U patent/SG10201908773UA/en unknown
- 2016-03-18 BR BR112017019966A patent/BR112017019966A2/pt not_active IP Right Cessation
- 2016-03-18 AU AU2016235472A patent/AU2016235472A1/en not_active Abandoned
- 2016-03-18 US US15/559,902 patent/US20180073019A1/en not_active Abandoned
- 2016-03-18 HK HK18113373.0A patent/HK1254230A1/zh unknown
- 2016-03-18 EP EP16769422.3A patent/EP3271021A4/en active Pending
- 2016-03-18 JP JP2018500271A patent/JP2018510219A/ja active Pending
- 2016-03-18 SG SG11201707458VA patent/SG11201707458VA/en unknown
- 2016-03-18 MX MX2017011829A patent/MX2017011829A/es unknown
-
2017
- 2017-09-13 IL IL254480A patent/IL254480A0/en unknown
- 2017-09-13 ZA ZA2017/06236A patent/ZA201706236B/en unknown
-
2022
- 2022-07-15 US US17/866,261 patent/US20230193257A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,253 patent/US20250250562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510219A5 (enExample) | ||
| Bobbin et al. | RNA interference approaches for treatment of HIV-1 infection | |
| JP2016534125A5 (enExample) | ||
| JP7118588B2 (ja) | Ｈｉｖ感染のｒｎａガイド処置のための方法および組成物 | |
| US20190032057A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| US11566237B2 (en) | Silencing of DUX4 by recombinant gene editing complexes | |
| EP3463290A1 (en) | Negative feedback regulation of hiv-1 by gene editing strategy | |
| CN107949424A (zh) | Tat诱导的基于crispr/核酸内切酶的基因编辑 | |
| Al-Allaf et al. | LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives | |
| WO2018194876A1 (en) | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents | |
| Guan et al. | How Advanced are Nanocarriers for Effective Subretinal Injection? | |
| Chiru et al. | Delivering the" Blueprints" or" DNA Repairing Kits" Instead of Drugs in the Treatment of Congenital Hemoglobinopathies | |
| Saha et al. | Advancements in modern biotechnological approaches for combating HIV infection | |
| HK40114560A (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| HK40000290A (en) | Excision of retroviral nucleic acid sequences |